Addex Therapeutics name Roger Mills to newly created position of Chief Medical Officer

Addex Therapeutics, a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders such is Parkinson’s disease, has appointed, Roger Mills M.D., to the newly created position of Chief Medical Officer.


Dr. Roger Mills


Dr. Mills brings more than 25 years of biopharmaceutical industry experience at both global pharmaceutical companies and biotechnology companies, including Acadia Pharmaceuticals, Pfizer, Gilead Sciences, Abbott Laboratories and Wellcome, across a spectrum of disease areas.  His extensive track record includes managing drug development programs from Investigational New Drug Application preparation through to post-marketing and OTC products, including NUPLAZID(TM) for the treatment of Parkinson’s disease psychosis, as well as regulatory affairs and business development activities.  Most recently, Dr. Mills was with Acadia Pharmaceuticals for nine years, serving as Executive Vice President, Development and Chief Medical Officer.  In this role, he oversaw the largest ever international phase III program in Parkinson’s disease psychosis, and led the Company’s New Drug Application submission to the US Food and Drug Administration (FDA) for NUPLAZID, which was subsequently approved and remains the first and only medication approved by the FDA in this indication.

“We are delighted to welcome Roger to the Addex team, he brings a unique blend of drug development expertise, commercial experience and US public biotechnology company operations knowledge,” said Tim Dyer, CEO of Addex.

Dyer also said he expects Mills to be a part in helping tackle Parkinson’s disease. Dyer said: “Roger’s experience in helping to successfully and significantly grow Acadia will be invaluable to Addex as we continue to execute on our strategy to develop dipraglurant for levodopa-induced dyskinesia associated with Parkinson’s disease.”successfully and significantly grow Acadia will be invaluable to Addex as we continue to execute on our strategy to develop dipraglurant for levodopa-induced dyskinesia associated with Parkinson’s disease.”

“I am excited to join Addex at such a critical juncture in the company’s corporate development,” said Dr. Mills “Addex’s development pipeline holds significant promise, and I look forward to applying my broad experience in the pharmaceutical industry and dealing with regulatory agencies to successfully advance the company’s product candidates.”

Dr. Mills currently serves as a Visiting Professor at the Centre for Age Related Diseases, Institute of Psychiatry, Psychology and Neuroscience, King’s College London.  He received his medical degree from Imperial College, Charing Cross Hospital Medical School, London, UK.

Allosteric modulators – which is in the focus of Addex, are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional “orthosteric” biological or small molecule drugs.

Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex’s lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a phase IIa POC in Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s